Joint Symposium ESMO-JSMO: How to overcome resistance of target therapy for lung cancer
Development of a nationwide genomic screening network for lung cancer with rare driver oncogenes and investigation of the mechanism of drug resistance
Date
08 Oct 2016Session
Joint Symposium ESMO-JSMO: How to overcome resistance of target therapy for lung cancerPresenters
Shingo MatsumotoAuthors
S. MatsumotoAuthor affiliations
- Department Of Thoracic Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Introduction
Presenter: Yuichiro Ohe
Session: Joint Symposium ESMO-JSMO: How to overcome resistance of target therapy for lung cancer
Resources:
Slides
Webcast
Treatment decisions at ALK TKI resistance
Presenter: Maurice Perol
Session: Joint Symposium ESMO-JSMO: How to overcome resistance of target therapy for lung cancer
Resources:
Slides
Webcast
Conclusions and clinical perspectives
Presenter: Solange Peters
Session: Joint Symposium ESMO-JSMO: How to overcome resistance of target therapy for lung cancer
Resources:
Slides
Webcast